Login  /  Register  | 3 premium articles left before you must register.
Wed., Jul. 30, 2014
Pfizer loses appeal in U.S. Supreme Court

Pfizer Inc. lost an appeal to the U.S. Supreme Court Monday over the off-label marketing of the epilepsy remedy Neurontin.

The decision, made without comment, meant that Pfizer likely will have to pay a $142 million award to Kaiser Foundation while also facing two other similar suits, including one brought by Aetna Inc. and another filed by insurers, union funds and employers who paid for Neurontin.

Insurers claim that Pfizer's Warner-Lambert division promoted Neurontin for neuropathic pain and bipolar disorder, among other uses. Pfizer had argued that a Boston appeals court had not applied the proper standards for determining guilt or innocence.

Copyright 2012 The Day Publishing Company
 Full Site | Sign up for text alerts | Deal of The Day | Contact Us | Member Services